1,871
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Non-fatal intoxications involving the novel benzodiazepine clonazolam: case series from the Emerging Drugs Network of Australia – Victoria project

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 290-293 | Received 08 Dec 2022, Accepted 16 Feb 2023, Published online: 29 Mar 2023

References

  • Hester JB, Jr. Rudzik AD, Kamdar BV. 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines which have central nervous system depressant activity. J Med Chem. 1971;14(11):1078–1081.
  • European Monitoring Centre for Drugs and Drug Addiction. New benzodiazepines in Europe – a review. Luxembourg: Publications Office of the European Union; 2021. Available from: https://www.emcdda.europa.eu/publications/rapid-communications/new-benzodiazepines-europe-review_en
  • World Health Organization. Critical review report: clonazolam. Gevena: World Health Organization; 2020. Available from: https://www.who.int/docs/default-source/controlled-substances/43rd-ecdd/final-clonazolam-a.pdf?sfvrsn=b8b10967_4
  • Carpenter JE, Murray BP, Dunkley C, et al. Designer benzodiazepines: a report of exposures recorded in the national poison data system, 2014-2017. Clin Toxicol. 2019;57(4):282–286.
  • Sommerfeld-Klatta K, Łukasik-Głębocka M, Teżyk A, et al. Clonazolam a new designer benzodiazepine intoxication confirmed by blood concentration. Forensic Sci Int. 2020;310(1):110237.
  • Moore C, Hammers J, Marshall P. Clonazolam intoxication case report: danger of designer benzodiazepines. Am J Forensic Med Pathol. 2022;43(4):372–375.
  • Syrjanen R, Schumann J, Fitzgerald J, et al. The emerging drugs network of Australia - Victoria clinical registry: a state-wide illicit substance surveillance and alert network. Emerg Med Australas. 2023;35(1):82–88.
  • Blakey K, Thompson A, Matheson A, et al. What’s in fake 'xanax’?: a dosage survey of designer benzodiazepines in counterfeit pharmaceutical tablets. Drug Test Anal. 2022;14(3):525–530.
  • Zawilska JB, Wojcieszak J. An expanding world of new psychoactive substances-designer benzodiazepines. Neurotoxicology. 2019;73:8–16.
  • Waters L, Manchester KR, Maskell PD, et al. The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines. Sci Justice. 2018;58(3):219–225.
  • van Wijk XMR, Yun C, Hooshfar S, et al. A liquid-chromatography high-resolution mass spectrometry method for non-FDA approved benzodiazepines. J Anal Toxicol. 2019;43(4):316–320.
  • Meyer MR, Bergstrand MP, Helander A, et al. Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes. Anal Bioanal Chem. 2016;408(13):3571–3591.
  • Kagota S, Morikawa K, Ishida H, et al. Vasorelaxant effects of benzodiazepines, non-benzodiazepine sedative-hypnotics, and tandospirone on isolated rat arteries. Eur J Pharmacol. 2021;892:173744.
  • Agelink MW, Majewski TB, Andrich J, et al. Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam. Crit Care Med. 2002;30(5):997–1006.